We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reviewing Heart Risk Data for Parkinson’s Drug Stalevo
FDA Reviewing Heart Risk Data for Parkinson’s Drug Stalevo
August 27, 2010
The FDA is evaluating clinical trial data that suggest Orion Pharma and Novartis’ Parkinson’s drug Stalevo may be associated with a slightly increased risk for cardiovascular (CV) events.